ACON Aclarion, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1635077 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.0%
TTM net income YoY-37.9%
TTM EPS YoY99.7%
Revenue 3-yr CAGR5.4%
Net income 3-yr CAGR—
Margins
Gross margin29.1%
Operating margin-10,789.2%
Net margin-10,260.0%
FCF margin—
EBITDA margin-10,662.3%
Returns
ROE-74.1%
ROA-69.7%
ROIC (approx.)-958.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio14.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $75,730 | $45,724 |
| Cost of revenue | $68,902 | $84,658 |
| Gross profit | $6,828 | -$38,934 |
| R&D expense | $1.03M | $888,766 |
| SG&A expense | $4.12M | $3.61M |
| Operating income | -$7.05M | -$5.51M |
| Interest expense | — | $64,084 |
| Pretax income | -$7.23M | -$6.99M |
| Income tax | $0 | $0 |
| Net income | -$7.23M | -$6.99M |
| EBITDA | -$6.82M | -$5.32M |
| EPS (basic) | -13.61 | -7,478.90 |
| EPS (diluted) | -13.61 | -7,478.90 |
| Weighted avg. shares (diluted) | 532,036 | 943 |
| Banking | ||
| Deposits | — | $463,661 |
| Balance sheet | ||
| Cash & equivalents | $12.02M | $463,661 |
| Receivables | $29,680 | $18,326 |
| Current assets | $12.40M | $824,279 |
| PP&E, net | $24,169 | $5,499 |
| Intangibles | $1.25M | $1.29M |
| Total assets | $13.67M | $2.12M |
| Current liabilities | $837,287 | $1.15M |
| Total liabilities | $837,287 | $1.15M |
| Shareholders' equity | $12.84M | $970,057 |
| Shares outstanding | 854,371 | 1,370 |
| Cash flow statement | ||
| Operating cash flow | -$7.16M | -$5.27M |
| Capital expenditure | $21,528 | $5,115 |
| Free cash flow | -$7.19M | -$5.28M |
| Investing cash flow | -$203,902 | -$321,937 |
| Financing cash flow | $18.95M | $5.03M |
| Depreciation & amortization | $227,406 | $193,139 |
| Stock-based compensation | $105,368 | $287,455 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.